MaxCyte Inc
LSE:MXCT
MaxCyte Inc
Cash from Operating Activities
MaxCyte Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MaxCyte Inc
LSE:MXCT
|
Cash from Operating Activities
-$21.7m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash from Operating Activities
$8.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
Danaher Corp
NYSE:DHR
|
Cash from Operating Activities
$7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Cash from Operating Activities
$965.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Agilent Technologies Inc
NYSE:A
|
Cash from Operating Activities
$2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash from Operating Activities
$2.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
See Also
What is MaxCyte Inc's Cash from Operating Activities?
Cash from Operating Activities
-21.7m
USD
Based on the financial report for Dec 31, 2023, MaxCyte Inc's Cash from Operating Activities amounts to -21.7m USD.
What is MaxCyte Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-16%
Over the last year, the Cash from Operating Activities growth was -47%. The average annual Cash from Operating Activities growth rates for MaxCyte Inc have been -35% over the past three years , -16% over the past five years .